The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
 
Ferdinandos Skoulidis
Honoraria - Bristol-Myers Squibb
 
Kathryn Cecilia Arbour
Consulting or Advisory Role - AstraZeneca
 
Matthew David Hellmann
Stock and Other Ownership Interests - Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Mirati Therapeutics; Nektar; Novartis; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Pradnya Dinkar Patil
No Relationships to Disclose
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Bluebird Bio; Gilead Sciences; Merck; Portola Pharmaceuticals
Consulting or Advisory Role - Boehringer Ingelheim
Other Relationship - Novartis
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - Bristol-Myers Squibb
 
Joseph Christopher Murray
No Relationships to Disclose
 
Jessica Hellyer
No Relationships to Disclose
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Jounce Therapeutics; Loxo; Merck; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Anastasios Dimou
No Relationships to Disclose
 
Christine M. Bestvina
Consulting or Advisory Role - Abbvie
 
Catherine A. Shu
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Janssen (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Jonathan W. Riess
Consulting or Advisory Role - Abbvie; Biodesix; Celgene; Loxo; Medtronic; Spectrum Pharmaceuticals; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Collin Michael Blakely
Consulting or Advisory Role - Jazz Pharmaceuticals
Research Funding - Clovis Oncology (Inst); Ignyta (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Novartis
 
Chad Victor Pecot
Consulting or Advisory Role - Medscape
Patents, Royalties, Other Intellectual Property - Methods and compositions using RNA Interference for inhibition of KRAS (Inst)
 
Laura Mezquita
No Relationships to Disclose
 
Fabrizio Tabbò
No Relationships to Disclose
 
Matthias Scheffler
Honoraria - Boehringer Ingelheim; Healthcare Consulting Cologne; Mediolanum Farmaceutici; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Mediolanum Farmaceutici; Roche; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim; Mediolanum Farmaceutici
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations